Intelligence Β· Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe β grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring β€24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months β use filters for patent-cliff planning.
-
US 7129332
Anti-EGFRvIII scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
granted -
US 7129052
Peptides and their utility in modulation of behavior of cells expressing Ξ±3Ξ²1 integrins
granted -
US 7129342
Infectious cDNA clone of GB virus B and uses thereof
granted -
US 7128894
Contrast enhancing solution for use in confocal microscopy
granted -
US 7125553
Methods of inducing immune tolerance using immunotoxins
granted -
US 7122624
Parathyroid hormone receptor ligands
granted -
US 7118738
Recombinant pox virus for immunization against MUC1 tumor-associated antigen
granted -
US 7118758
Transformed bacteria producing CS6 antigens as vaccines
granted -
US 7115262
Chimeric protein for prevention and treatment of HIV infection
granted -
US 7112332
Oral or intranasal vaccines using hydrophobic complexes having proteosomes and lipopolysaccharides
granted -
US 7109323
Formulation of boronic acid compounds
granted -
US 7109380
Cyclopentenedione antifungal compounds and methods for their use
granted -
US 7109245
Vasoconstrictor cannabinoid analogs
granted -
US 7108981
Specific binding agents for KSHV vIL-6 that neutralize a biological activity
granted -
US 7105488
G protein-coupled receptor antagonists
granted -
US 7105169
Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
granted -
US 7105170
Latent human tuberculosis model, diagnostic antigens, and methods of use
granted -
US 7105643
Monoclonal antibodies specific for crack cocaine metabolites, a cell line producing the same, and crack cocaine conjugates
granted -
US 7101541
Utilization of non-viral sequences for minus-strand DNA transfer and gene reconstitution
granted -
US 7101548
Functional role of adrenomedullin (AM) and the gene-related product (PAMP) in human pathology and physiology
granted -
US 7101547
Method for the prevention and treatment of diseases caused by an inflammatory response mediated by endogenous substance P by using anti-substance P antibodies
granted -
US 7097965
Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein
granted -
US 7094598
Development of a preventive vaccine for filovirus infection in primates
granted -
US 7094045
Microencapsulation system and method
granted -
US 7094405
Peptides which elicit a high neutralizing antibody titer, cytotoxic T lymphocyte response and T helper cell response in a broad range of MHC type recipients
granted -
US 7094404
Method for treating malignancy and autoimmune disorders in humans using tac antibodies
granted -
US 7094408
Immunogenicity using a combination of DNA and vaccinia virus vector vaccines
granted -
US 7094411
Avirulent, immunogenic flavivirus chimeras
granted -
US 7094406
Enterically transmitted non-A/non-B hepatitis viral agent and characteristic epitopes thereof
granted -
US 7094883
Monoclonal antibody which agglutinates E. coli having the CS4-CFA/I family protein
granted -
US 7090852
Venezuelan equine encephalitis virus replicon encoding marburg virus proteins
granted -
US 7087589
Methanocarba cycloakyl nucleoside analogues
granted -
US 7087234
Recombinant multivalent viral vaccine
granted -
US 7087591
21-substituted progesterone derivatives as new antiprogestational agents
granted -
US 7084266
Cloned genome of infectious hepatitus C virus of genotype 2A and uses thereof
granted -
US 7084239
Cancer peptides of NY-ESO-1/CAG-3
granted -
US 7084132
Artemisinins with improved stability and bioavailability for therapeutic drug development and application
granted -
US 7081524
O2-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates
granted -
US 7081452
Scorpionate-like pendant macrocyclic ligands, complexes and compositions thereof, and methods of using same
granted -
US 7081529
Recombinant vaccine against botulinum neurotoxin
granted -
US 7081518
Anti-mesothelin antibodies having high binding affinity
granted -
US 7078507
Synthetic genes for malarial proteins and methods of use
granted -
US 7078508
Ixodes scapularis tissue factor pathway inhibitor
granted -
US 7074410
Modified HCV peptide vaccines
granted -
US 7070972
Janus family kinases and identification of immune modulators
granted -
US 7070790
Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
granted -
US 7070788
Follicle stimulating hormone superagonists
granted -
US 7067122
Modified live Edwardsiella tarda vaccine for aquatic animals
granted
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory